Elevance Health Inc. (ELV) Stock Forecast
ELV analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.18 / 5 from 22 analysts
- Price target
- $451.71 average of analyst targets
- Upside to target
- +5.5% from the latest close
- Next earnings
- October 21, 2026 EPS estimate $4.66
- 52-week range
- $280.74 – $428.43
ELV analyst ratings
22 analystsNumber of analysts at each rating.
ELV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ELV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.69 | $4.55 | $4.99 | $6.03 | −22.1% | 19 |
| Current fiscal year (2026) | $27.24 | $27.00 | $28.25 | $30.29 | −10.1% | 22 |
| Next fiscal year (2027) | $29.60 | $29.00 | $31.00 | $27.24 | +8.6% | 22 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ELV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $49.16B | $48.55B | $50.19B | −1.8% | 11 |
| Current fiscal year (2026) | $196.44B | $192.66B | $199.06B | −0.6% | 12 |
| Next fiscal year (2027) | $200.24B | $193.08B | $209.25B | +1.9% | 11 |
ELV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ELV revenue: reported and forecast
ELV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $5.07 | $4.66 | $4.67 | $4.66 | $4.69 | −7.4% | 3 up · 1 down |
| Current fiscal year (2026) | $26.91 | $27.16 | $27.16 | $27.20 | $27.24 | +1.2% | 3 up · 0 down |
| Next fiscal year (2027) | $29.32 | $29.63 | $29.61 | $29.58 | $29.60 | +0.9% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ELV earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ELV beat in 9 of 12.
What analysts expect from ELV
22 analysts cover Elevance Health; their consensus rating is buy (4.18 on a 1–5 scale, where 5 is a strong buy). The average price target is $451.71, 5.5% above the latest close of $428.26. Analysts expect earnings of $27.24 per share for 2026, −10.1% from a year earlier. For 2027 the average estimate is $29.60 per share on revenue of $200.2 billion. Elevance Health beat the EPS estimate in 9 of the last 12 quarters.
Related: ELV income statement, ELV key metrics, ELV chart. See the ELV stock overview for the latest quote and news.
ELV forecast FAQ
What is Elevance Health's price target?
The average analyst price target for Elevance Health is $451.71, 5.5% above the latest close of $428.26.
Is Elevance Health a buy, hold or sell?
Of 22 analysts covering Elevance Health, 12 rate it a strong buy, 2 a buy, 8 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Elevance Health's EPS forecast?
Analysts forecast $27.24 per share for 2026 (range $27.00 to $28.25); for 2027 the estimate is $29.60.
What is Elevance Health's revenue forecast?
The average revenue estimate for 2026 is $196.4 billion, growth of −0.6%; for 2027 it is $200.2 billion.
When does Elevance Health report earnings?
Elevance Health is expected to report results for the quarter ending September 30, 2026 on October 21, 2026 before the market opens; the EPS estimate is $4.66.
Does Elevance Health usually beat earnings estimates?
Elevance Health reported EPS at or above the analyst estimate in 9 of the last 12 quarters.